Antagonistic Effects of p53 and HIF1A on microRNA-34a Regulation of PPP1R11 and STAT3 and Hypoxia-induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells

Gastroenterology

Volumn 153, Issue 2, 2017, Pages 505-520

  Li, Huihui ^a   Rokavec, Matjaz ^a   Jiang, Longchang ^a   Horst, David ^a,b   Hermeking, Heiko ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Chemo Resistance; Colon Cancer; Signal Transduction; Tumor Progression

Indexed keywords

F ACTIN; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA; MICRORNA 34A; MICRORNA 34B; MICRORNA 34C; OXYGEN; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN P53; PROTEIN PHOSPHATASE 1 REGULATORY INHIBITOR SUBUNIT 11; STAT3 PROTEIN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; HIF1A PROTEIN, MOUSE; MIRN34 MICRORNA, MOUSE; PPP1R11 PROTEIN, MOUSE;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CANCER RESISTANCE; CELL ACTIVATION; CELL HYPOXIA; CELL INVASION; CELL MIGRATION; CHROMATIN IMMUNOPRECIPITATION; COLON CARCINOGENESIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; ECTOPIC EXPRESSION; EPITHELIAL MESENCHYMAL TRANSITION; GENE REPRESSION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; METASTASIS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OXYGEN CONCENTRATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TUMOR XENOGRAFT; UPREGULATION; ADENOMA; ANIMAL; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; HYPOXIA; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR HYPOXIA; TUMOR SUPPRESSOR GENE;

ADENOMA; ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENOTYPE; HUMANS; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICRORNAS; PROTEIN PHOSPHATASE 1; STAT3 TRANSCRIPTION FACTOR; TUMOR HYPOXIA;

EID: 85024896147     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.04.017     Document Type: Article

References (46)

1. Semenza, G.L., Hypoxia-inducible factors in physiology and medicine. Cell 148 (2012), 399–408.
2. Leith, J.T., Padfield, G., Faulkner, L., et al. Hypoxic fractions in xenografted human colon tumors. Cancer Res 51 (1991), 5139–5143.
3. Thiery, J.P., Acloque, H., Huang, R.Y., et al. Epithelial-mesenchymal transitions in development and disease. Cell 139 (2009), 871–890.
4. De Bock, K., Mazzone, M., Carmeliet, P., Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?. Nat Rev Clin Oncol 8 (2011), 393–404.
5. Rokavec, M., Oner, M.G., Hermeking, H., lnflammation-induced epigenetic switches in cancer. Cell Mol Life Sci 73 (2016), 23–39.
6. Vaupel, P., Mayer, A., Hockel, M., Tumor hypoxia and malignant progression. Methods Enzymol 381 (2004), 335–354.
7. Brown, J.M., Giaccia, A.J., The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58 (1998), 1408–1416.
8. Semenza, G.L., HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 123 (2013), 3664–3671.
9. Zhong, H., De Marzo, A.M., Laughner, E., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59 (1999), 5830–5835.
10. Wenger, R.H., Stiehl, D.P., Camenisch, G., Integration of oxygen signaling at the consensus HRE. Sci STKE, 2005, 2005, re12.
11. Semenza, G.L., Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29 (2010), 625–634.
12. Fan, L.F., Dong, W.G., Jiang, C.Q., et al. Role of Hypoxia-inducible factor-1 alpha and Survivin in colorectal carcinoma progression. Int J Colorectal Dis 23 (2008), 1057–1064.
13. Chen, Z., He, X., Xia, W., et al. Prognostic value and clinicopathological differences of HIFs in colorectal cancer: evidence from meta-analysis. PLoS One, 8, 2013, e80337.
14. Mattagajasingh, S.N., Yang, X.P., Irani, K., et al. Activation of Stat3 in endothelial cells following hypoxia-reoxygenation is mediated by Rac1 and protein Kinase C. Biochim Biophys Acta 1823 (2012), 997–1006.
15. Wen, Z., Zhong, Z., Darnell, J.E. Jr., Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82 (1995), 241–250.
16. Tkach, M., Rosemblit, C., Rivas, M.A., et al. p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth. Endocr Relat Cancer 20 (2013), 197–212.
17. Sakaguchi, M., Oka, M., Iwasaki, T., et al. Role and regulation of STAT3 phosphorylation at Ser727 in melanocytes and melanoma cells. J Invest Dermatol 132 (2012), 1877–1885.
18. Aziz, M.H., Hafeez, B.B., Sand, J.M., et al. Protein kinase Cvarepsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2). Oncogene 29 (2010), 3100–3109.
19. Lin, G.S., Chen, Y.P., Lin, Z.X., et al. STAT3 serine 727 phosphorylation influences clinical outcome in glioblastoma. Int J Clin Exp Pathol 7 (2014), 3141–3149.
20. Graeber, T.G., Osmanian, C., Jacks, T., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379 (1996), 88–91.
21. Aziz, M.H., Manoharan, H.T., Church, D.R., et al. Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. Cancer Res 67 (2007), 8828–8838.
22. Moreno-Bueno, G., Peinado, H., Molina, P., et al. The morphological and molecular features of the epithelial-to-mesenchymal transition. Nat Protoc 4 (2009), 1591–1613.
23. Hermeking, H., MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer 12 (2012), 613–626.
24. Rokavec, M., Li, H., Jiang, L., et al. The p53/miR-34 axis in development and disease. J Mol Cell Biol 6 (2014), 214–230.
25. Rokavec, M., Oner, M.G., Li, H., et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest 124 (2014), 1853–1867.
26. Siemens, H., Jackstadt, R., Hunten, S., et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 10 (2011), 4256–4271.
27. Zgheib, C., Zouein, F.A., Chidiac, R., et al. Calyculin A reveals serine/threonine phosphatase protein phosphatase 1 as a regulatory nodal point in canonical signal transducer and activator of transcription 3 signaling of human microvascular endothelial cells. J Interferon Cytokine Res 32 (2012), 87–94.
28. Haridas, V., Nishimura, G., Xu, Z.X., et al. Avicin D: a protein reactive plant isoprenoid dephosphorylates Stat 3 by regulating both kinase and phosphatase activities. PLoS One, 4, 2009, e5578.
29. Jiang, L., Hermeking, H., miR-34a and miR-34b/c suppress intestinal tumorigenesis. Cancer Res 77 (2017), 2746–2758.
30. Fischer, K.R., Durrans, A., Lee, S., et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527 (2015), 472–476.
31. Wurzer, J.C., Tallarida, R.J., Sirover, M.A., New mechanism of action of the cancer chemotherapeutic agent 5-fluorouracil in human cells. J Pharmacol Exp Ther 269 (1994), 39–43.
32. Bunz, F., Hwang, P.M., Torrance, C., et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104 (1999), 263–269.
33. Muzny, D.M., Bainbridge, M.N., Chang, K., et al. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (2012), 330–337.
34. Kahlert, C., Lahes, S., Radhakrishnan, P., et al. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin Cancer Res 17 (2011), 7654–7663.
35. Leung, A.K., Sharp, P.A., MicroRNA functions in stress responses. Mol Cell 40 (2010), 205–215.
36. Sullivan, N.J., Sasser, A.K., Axel, A.E., et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28 (2009), 2940–2947.
37. Kawata, M., Koinuma, D., Ogami, T., et al. TGF-beta-induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by pro-inflammatory cytokines derived from RAW 264.7 macrophage cells. J Biochem 151 (2012), 205–216.
38. Fan, F., Samuel, S., Evans, K.W., et al. Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Med 1 (2012), 5–16.
39. Wang, H., Wang, H.S., Zhou, B.H., et al. Epithelial-mesenchymal transition (EMT) induced by TNF-alpha requires AKT/GSK-3beta-mediated stabilization of snail in colorectal cancer. PLoS One, 8, 2013, e56664.
40. Bowen, K.A., Doan, H.Q., Zhou, B.P., et al. PTEN loss induces epithelial—mesenchymal transition in human colon cancer cells. Anticancer Res 29 (2009), 4439–4449.
41. Siemens, H., Neumann, J., Jackstadt, R., et al. Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and beta-catenin predicts distant metastasis of colon cancer. Clin Cancer Res 19 (2013), 710–720.
42. Kaller, M., Liffers, S.T., Oeljeklaus, S., et al. Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol Cell Proteomics, 10, 2011 M111.010462.
43. Bader, A.G., miR-34—a microRNA replacement therapy is headed to the clinic. Front Genet, 3, 2012, 120.
44. Wiggins, J.F., Ruffino, L., Kelnar, K., et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 70 (2010), 5923–5930.
45. Wang, X., Li, J., Dong, K., et al. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal 27 (2015), 443–452.
46. Cortez, M.A., Ivan, C., Valdecanas, D., et al. PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst, 2016, 108.